NASDAQ: EPRXEupraxia Pharmaceuticals Inc Stock
$3.29+0.12 (+3.79%)
Updated Apr 17, 2025
EPRX Price
$3.29
Fair Value Price
N/A
Market Cap
$117.26M
52 Week Low
$2.20
52 Week High
$4.48
P/E
-4.33x
P/B
3.51x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$25.74M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$30M
Beta
0.52
Next Earnings
Jun 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
EPRX Overview
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. It also is involved in the development of product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EPRX's potential to beat the market
- EPRX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
EPRX
RankedUnranked of 463
RankedUnranked of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important EPRX news, forecast changes, insider trades & much more!
EPRX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EPRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EPRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
EPRX is good value based on its book value relative to its share price (3.51x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
EPRX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more EPRX due diligence checks available for Premium users.
Valuation
EPRX fair value
Fair Value of EPRX stock based on Discounted Cash Flow (DCF)
Price
$3.29
Fair Value
$0.26
Overvalued by
1,180.02%
EPRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EPRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.33x
Industry
-177.72x
Market
27.98x
EPRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.51x
Industry
4.05x
EPRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
EPRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$7.5M
Profit Margin
0%
EPRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$34.9M
Liabilities
$3.1M
Debt to equity
0.09
EPRX's short-term assets ($34.44M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EPRX's short-term assets ($34.44M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EPRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.0M
Investing
-$43.8k
Financing
$31.7M
EPRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EPRX vs Biotech Stocks
Eupraxia Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.